News

Solzira is the subject of a new drug application (NDA) that is under review by the FDA as a potential treatment for moderate-to-severe primary restless legs syndrome (RLS).

As part of the agreement, Syntonix gains access to Zenobia’s technology and expertise in structural biology, crystallization and X-ray structure determination. Zenobia has completed three unique protein structures

Simponi is a new, human anti-tumor necrosis factor (TNF) monoclonal antibody that was generated by Medarex’s UltiMAb technology that targets and neutralizes both the soluble and membrane-bound forms

The long-term cardiac monitoring for detection of atrial fibrillation (AF) after cryptogenic stroke is a pilot study involving five centers in Canada and the US. The primary endpoint

Berlin Heart, a developer and distributor of implantable and external ventricular assist devices, has received its first marketing approval in North America. The Excor Pediatric ventricular assist device

David Ramsay, Halozyme’s current CFO, will transition to the new position of vice president of corporate development. Mr Ramsay joined Halozyme as CFO in 2003. Mr Gustafson brings

Mr Beasley has joined Bard in 1989 and advanced through the sales and marketing organizations prior to being promoted to president of Bard Access Systems in 2003 and

Between 2004 and 2008, Mr Murphy was senior vice president and treasurer of Time Warner. Between 2001 and 2004, he was vice president and treasurer of Time Warner.

According to Bedford, Fluconazole injection is an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is also indicated for the prophylaxis of candidiasis. This product